Relationship between glucocorticoids and viral load during the Omicron wave in mainland China.
COVID-19
Cytokines
Glucocorticoids
Viral clearance
Viral load
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
21
09
2023
accepted:
07
11
2023
medline:
24
11
2023
pubmed:
23
11
2023
entrez:
23
11
2023
Statut:
epublish
Résumé
Coronavirus disease 19 (COVID-19) is a major public health problem that cannot be ignored. As a widely used drug in the treatment of COVID-19, whether glucocorticoids may accelerate the clearance of COVID-19 is still not clear, and the glucocorticoids may improve the prognosis of patients is also controversial. Therefore, to explore the relationship between COVID-19 viral load and the use of glucocorticoids we designed this study. Patients with COVID-19 infection who were admitted to the emergency department of Peking Union Medical College Hospital from the end of 2022 to early 2023 were enrolled in this study. Characteristics of baseline, clinical and laboratory evaluation especially immunological indicator and daily viral load were carefully collected. Kolmogorov-Smirnov test, Student's t test, Mann-Whitney U test and proportional-hazards model (Cox model) were chosen as appropriate for comparison of variables. By comparing the daily COVID-19 viral load and prognosis of patients with and without glucocorticoid therapy, we found that glucocorticoids did not statistically enhance the clearance or replication of COVID-19, nor did it change the 28-days and in-hospital mortality. However, glucocorticoid therapy may be a favorable factor for COVID-19 negative conversion in Cox model. The inflammatory factors in patients with glucocorticoid therapy were significantly decreased. We believe that the real effect of glucocorticoids may be to improve the destruction of host immune system caused by inflammatory storm through host immune regulation and then achieve the improvement of clinical symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 19 (COVID-19) is a major public health problem that cannot be ignored. As a widely used drug in the treatment of COVID-19, whether glucocorticoids may accelerate the clearance of COVID-19 is still not clear, and the glucocorticoids may improve the prognosis of patients is also controversial. Therefore, to explore the relationship between COVID-19 viral load and the use of glucocorticoids we designed this study.
METHODS
METHODS
Patients with COVID-19 infection who were admitted to the emergency department of Peking Union Medical College Hospital from the end of 2022 to early 2023 were enrolled in this study. Characteristics of baseline, clinical and laboratory evaluation especially immunological indicator and daily viral load were carefully collected. Kolmogorov-Smirnov test, Student's t test, Mann-Whitney U test and proportional-hazards model (Cox model) were chosen as appropriate for comparison of variables.
RESULTS
RESULTS
By comparing the daily COVID-19 viral load and prognosis of patients with and without glucocorticoid therapy, we found that glucocorticoids did not statistically enhance the clearance or replication of COVID-19, nor did it change the 28-days and in-hospital mortality. However, glucocorticoid therapy may be a favorable factor for COVID-19 negative conversion in Cox model. The inflammatory factors in patients with glucocorticoid therapy were significantly decreased.
CONCLUSIONS
CONCLUSIONS
We believe that the real effect of glucocorticoids may be to improve the destruction of host immune system caused by inflammatory storm through host immune regulation and then achieve the improvement of clinical symptoms.
Identifiants
pubmed: 37993863
doi: 10.1186/s12985-023-02235-4
pii: 10.1186/s12985-023-02235-4
pmc: PMC10666395
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
273Subventions
Organisme : The 2021 Medical and Health Science and Technology Innovation Project of Chinese Academy of Medical Sciences (project name: Construction of sepsis disease burden and risk stratification system
ID : 2021-I2M-1-062
Informations de copyright
© 2023. The Author(s).
Références
J Clin Virol. 2004 Dec;31(4):304-9
pubmed: 15494274
J Infect. 2020 Jul;81(1):e13-e20
pubmed: 32283144
Zhonghua Yi Xue Za Zhi. 2004 Jul 2;84(13):1073-8
pubmed: 15312504
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
JAMA. 2023 Apr 11;329(14):1183-1196
pubmed: 37039790
N Engl J Med. 2009 Nov 12;361(20):1935-44
pubmed: 19815859
Int J Mol Sci. 2021 Jun 23;22(13):
pubmed: 34201797
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Neuroimmunomodulation. 2015;22(1-2):20-32
pubmed: 25227506
JAMA Intern Med. 2022 Sep 1;182(9):906-916
pubmed: 35788622
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Intensive Care Med. 2018 Sep;44(9):1470-1482
pubmed: 30074052
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
J Comp Eff Res. 2020 Dec;9(18):1247-1254
pubmed: 33245242
Immun Inflamm Dis. 2022 Mar;10(3):e580
pubmed: 34904379
J Infect. 2010 Feb;60(2):168-74
pubmed: 20036689
J Infect. 2005 Aug;51(2):98-102
pubmed: 16038758
BMJ. 2020 Sep 4;370:m3379
pubmed: 32887691
Clin Infect Dis. 2011 Aug;53(4):326-33
pubmed: 21810744
Lancet. 2021 May 29;397(10289):2049-2059
pubmed: 34000257
BMJ. 2020 Jul 3;370:m2648
pubmed: 32620554
JAMA. 2020 Oct 6;324(13):1307-1316
pubmed: 32876695
Monaldi Arch Chest Dis. 2012 Jun;77(2):94-101
pubmed: 23193846
J Med Microbiol. 2003 Aug;52(Pt 8):715-720
pubmed: 12867568
Med Sci Monit. 2018 Jul 04;24:4617-4624
pubmed: 29972684
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
BMJ. 2020 May 22;369:m1985
pubmed: 32444460